| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $722,204 | 5 | 83 |
Sells | $66,843 | 1 | 17 |
| Phanstiel S. Louise | director | 3 | $494,722 | 0 | $0 | $494,722 |
| Raha Samraat S. | President and CEO | 1 | $199,844 | 0 | $0 | $199,844 |
| Bisaro Paul | director | 1 | $27,638 | 0 | $0 | $27,638 |
| Kumar Rashmi | director | 0 | $0 | 1 | $66,843 | $-66,843 |
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion …
Over the last 12 months, insiders at Myriad Genetics, Inc. have bought $722,204 and sold $66,843 worth of Myriad Genetics, Inc. stock.
On average, over the past 5 years, insiders at Myriad Genetics, Inc. have bought $722,204 and sold $2.94M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Phanstiel S. Louise (director) — $494,722. Raha Samraat S. (President and CEO) — $199,844. Bisaro Paul (director) — $27,638.
The last purchase of 7,500 shares for transaction amount of $27,638 was made by Bisaro Paul (director) on 2026‑05‑14.
| 2026-06-08 | Sale | Kumar Rashmi | director | 15,000 0.0161% | $4.46 | $66,843 | -2.51% | |
| 2026-05-14 | Bisaro Paul | director | 7,500 0.0078% | $3.69 | $27,638 | +17.40% | ||
| 2026-03-09 | Raha Samraat S. | President and CEO | 40,000 0.0415% | $5.00 | $199,844 | -7.80% | ||
| 2026-02-27 | Phanstiel S. Louise | director | 48,000 0.0521% | $4.66 | $223,728 | -1.95% | ||
| 2026-02-26 | Phanstiel S. Louise | director | 50,407 0.0534% | $4.80 | $242,105 | -6.58% | ||
| 2026-02-25 | Phanstiel S. Louise | director | 6,100 0.0065% | $4.74 | $28,890 | -5.02% | ||
| 2024-10-11 | Sale | DIAZ PAUL J | President and CEO | 15,000 0.0144% | $22.93 | $343,950 | -66.78% | |
| 2024-09-11 | Sale | DIAZ PAUL J | President and CEO | 15,000 0.0163% | $26.72 | $400,800 | -61.80% | |
| 2024-09-11 | Sale | Muzzey Dale | Chief Scientific Officer | 2,100 0.0022% | $26.17 | $54,961 | -61.80% | |
| 2024-09-09 | Sale | Dreismann Heinrich | director | 10,000 0.011% | $27.05 | $270,520 | -62.60% | |
| 2024-09-03 | Sale | Reitan Colleen F | director | 46,012 0.0516% | $27.95 | $1.29M | -62.13% | |
| 2024-08-21 | Sale | Ancona Margaret | SVP, Chief of Staff | 11,538 0.0127% | $27.82 | $320,987 | -55.84% | |
| 2024-08-19 | Sale | Kumar Rashmi | director | 7,500 0.0082% | $28.01 | $210,075 | -56.09% | |
| 2024-06-04 | Sale | SPIEGELMAN DANIEL K | director | 3,788 0.0041% | $22.05 | $83,525 | -31.62% | |
| 2024-06-03 | Sale | SPIEGELMAN DANIEL K | director | 3,788 0.0041% | $22.04 | $83,488 | -31.45% | |
| 2024-05-15 | Sale | DIAZ PAUL J | President and CEO | 75,000 0.0843% | $25.07 | $1.88M | -32.50% | |
| 2024-05-14 | Sale | DIAZ PAUL J | President and CEO | 95,000 0.1043% | $25.21 | $2.39M | -32.97% | |
| 2024-05-13 | Sale | DIAZ PAUL J | President and CEO | 57,844 0.0644% | $25.13 | $1.45M | -30.36% | |
| 2024-05-13 | Sale | Newcomer Lee Nisley | director | 6,200 0.007% | $25.30 | $156,860 | -30.36% | |
| 2023-12-01 | Sale | Riggsbee Richard Bryan | Chief Financial Officer | 30,000 0.0333% | $19.09 | $572,835 | +17.13% |
| Raha Samraat S. | President and CEO | 493104 0.5155% | $2.98M | 1 | 0 | |
| Phanstiel S. Louise | director | 281951 0.2948% | $1.7M | 4 | 2 | +79.17% |
| Bisaro Paul | director | 97441 0.1019% | $588,543.64 | 1 | 0 | |
| Capone Mark Christopher | President & C.E.O. | 440833 0.4609% | $2.66M | 1 | 16 | <0.0001% |
| McDade Ralph L | President Myriad RBM, Inc. | 122604 0.1282% | $740,528.16 | 1 | 1 | <0.0001% |
| HENDERSON JOHN T | director | 64353 0.0673% | $388,692.12 | 5 | 9 | +11.1% |
| GILBERT WALTER PHD | director | 54150 0.0566% | $327,066.00 | 1 | 16 | <0.0001% |
| ATTIYEH ROBERT S | director | 3000 0.0031% | $18,120.00 | 1 | 0 | +1.99% |
| Belle Gerald P. | director | 1200 0.0013% | $7,248.00 | 1 | 0 | <0.0001% |
| Increased Positions | 121 | +49.79% | 10M | +11.26% |
| Decreased Positions | 107 | -44.03% | 7M | -7.52% |
| New Positions | 32 | New | 741,074 | New |
| Sold Out Positions | 29 | Sold Out | 3M | Sold Out |
| Total Postitions | 257 | +5.76% | 95M | +3.74% |
| Blackrock, Inc. | $91,360.00 | 16% | 14.88M | -192,832 | -1.28% | 2025-09-30 |
| Vanguard Group Inc | $48,399.00 | 8.48% | 7.88M | -1M | -14.85% | 2025-09-30 |
| State Street Corp | $30,556.00 | 5.35% | 4.98M | +166,543 | +3.46% | 2025-09-30 |
| Millennium Management Llc | $29,155.00 | 5.11% | 4.75M | -176,387 | -3.58% | 2025-09-30 |
| Glenview Capital Management, Llc | $28,167.00 | 4.93% | 4.59M | 0 | 0% | 2025-09-30 |
| D. E. Shaw & Co., Inc. | $27,993.00 | 4.9% | 4.56M | +47,639 | +1.06% | 2025-09-30 |
| Morgan Stanley | $22,208.00 | 3.89% | 3.62M | -937,155 | -20.58% | 2025-09-30 |
| Jacobs Levy Equity Management, Inc | $14,999.00 | 2.63% | 2.44M | +1M | +157.01% | 2025-09-30 |
| Geode Capital Management, Llc | $13,663.00 | 2.39% | 2.23M | +2,207 | +0.1% | 2025-09-30 |
| Goldman Sachs Group Inc | $13,212.00 | 2.31% | 2.15M | +868,325 | +67.66% | 2025-09-30 |